Galenica Records Another Surge in Sales Growth

• Galenica Group reported strong sales growth of 4.4% in 2023, reaching CHF 3,746.0 million.
• The "Logistics & IT" segment posted strong growth of 4.9%, while the "Products & Care" segment saw sales growth of 3.3%.
• The overall pharmaceutical market's strong performance, with growth of 4.9%, particularly contributed to the sales growth.
• Galenica confirms its guidance for the 2023 financial year, with EBIT1 at roughly the same level as the previous year, and the outlook for the 2023 dividend at least at the same level as the previous year.
• The "Products & Care" segment achieved net sales of CHF 1,635.6 million (+3.3%) in financial year 2023.
• The "Logistics & IT" segment achieved net sales of CHF 3,077.0 million (+4.9%) in the 2023 financial year.

The next important date, Quarterly report, at Galenica is on 05.03.2024.

Galenica

-1,04 %

-2,15 %

-7,15 %

-11,70 %

-11,15 %

+27,30 %

+68,71 %

+81,17 %

ISIN:CH0360674466WKN:A2DN0K

• Intraday
• 5 Tage
• 1 Monat
• 3M
• 1 Jahr
• 3J
• 5J
• Max